EYEG Eyegate Pharmaceuticals, Inc.

0  -1%
Previous Close 2.02
Open 1.99
Price To book 0.00
Market Cap 20.37M
Shares 10,234,000
Volume 37,162
Short Ratio 0.31
Av. Daily Volume 1,043,100

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 top-line data released July 2016. Further data released December 5, 2016. Phase 2b trial to be initiated 1H 2017.
Ocular inflammation and pain post cataract surgery
Phase 3 enrollment to be completed 3Q 2017. Top-line data due 4Q 2017
Non-infectious anterior uveitis

Latest News

  1. EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.
  2. EYEG: Several Major Development Milestones Expected in 2017
  3. Top Biopharma Movers of the Past Week
  4. EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update
  5. Biotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS
  6. EyeGate Pharmaceuticals Licensing Deal Review and Breakdown
  7. ​Tiny Waltham biotech's market cap doubles after $103M Valeant licensing deal
  8. Valeant Acquires Eyegate Licensing Rights
  9. Tuesday’s Top Biopharma Movers
  10. Dow Higher for Eighth Straight Session as Retailers Rise
  11. Stock Futures Rise After Walmart, Home Depot Top Earnings Estimates
  12. EyeGate Pharma surges 15% on news of Valeant licensing agreement
  13. Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients
  14. EyeGate Pharmaceuticals Announces Executive Promotions
  15. EYEG: Positive OBG Clinical Data, Larger Study Already Planned
  16. Is This the Beginning of EyeGate’s Rally?
  17. EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects